ED
EDAP
EDAP TMS SA
$4.64
+0.98%
No data for this timeframe.
Vol
Analyst ConsensusBuy (67%)
Inst. Holders2 funds
Inst. Value$11.0M
Inst. Activity1 buys / 0 sells
Insider Activity1B / 0S
Insider Net $$42.2K
SEC Reports8
Press Releases3
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·CIK 0001041934·Prev Close $4.60
Recent Activity
May 29, 2026
SEC
EDAP TMS SA announced it will operate under the new corporate name 'FocalTherics' and change its Nasdaq ticker to 'FOCL'
8-K — Impact 4/10
May 29, 2026
other
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
<p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b><
May 14, 2026
SEC
EDAP TMS SA filed its management report for the 2025 fiscal year ahead of the June 26, 2026 annual general meeting. Cons
DEFA14A — Impact 6/10
May 14, 2026
SEC
EDAP TMS SA filed a DEFA14A providing notice of its 2026 Ordinary and Extraordinary General Meeting scheduled for June 2
DEFA14A — Impact 3/10
May 12, 2026
Insider
Mobeck Kenneth S. sold 120,000 shares
Chief Financial Officer @ $0.00 ($0.00)
May 12, 2026
Insider
Mobeck Kenneth S. sold 144,141 shares
Chief Financial Officer @ $0.00 ($0.00)
May 12, 2026
Insider
Shah Sanket sold 67,500 shares
Gen Counsel & Corp Secretary @ $0.00 ($0.00)
Inst.
UBS Group AG — ADD
238,220 shares ($545.5K)
Price Targets
$5.83
+35.0% upside
Strong Buy
Current $4.32
Low $3.00
Median $4.50
High $10.00
3 analysts
$3.00
$10.00
Analyst Ratings
2Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▲ +6.8% | $-0.24 — $-0.17 | -18% YoY | 2 |
| Next Q | $-0.23 ▼ -2.3% | $-0.23 — $-0.22 | -50% YoY | 2 |
| Current FY | $-0.82 ▲ +1.2% | $-0.86 — $-0.78 | -3% YoY | 2 |
| Next FY | $-0.59 | $-0.64 — $-0.54 | 28% YoY | 2 |
Latest Reports
NEUTRAL
8-K
4/10
EDAP TMS SA announced it will operate under the new corporate name 'FocalTherics' and change its Nasdaq ticker to 'FOCL'
May 29, 2026
BEARISH
DEFA14A
6/10
EDAP TMS SA filed its management report for the 2025 fiscal year ahead of the June 26, 2026 annual general meeting. Cons
May 14, 2026
NEUTRAL
Press
3/10
EDAP TMS announced a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinical research and phys
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $11.0M | — |
| WELLS FARGO & COMPANY/MN | $11.5K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Mobeck Kenneth | A | $0.00 |
| May 12, 2026 | Mobeck Kenneth | A | $0.00 |
| May 12, 2026 | Shah Sanket | A | $0.00 |
| May 12, 2026 | Shah Sanket | A | $0.00 |
| May 12, 2026 | WILLSEY LANCE | A | $0.00 |
2 institutional holders with $11.0M total value (3,355,580 shares) as of 2025-Q4. Top holders: MORGAN, WELLS.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 3,352,080 | $11.0M | 99.9% | — |
| 2 | WELLS FARGO & COMPANY/MN | 3,500 | $11.5K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | ADD | 178,449 | 238,220 | +33.5% | $545.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 38,459 | 178,449 | +364.0% | $294.4K | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,906 | 45,864 | +2306.3% | $101.4K | 2024-Q4 |
6 unique insiders with 1 transactions. Net insider value: $42.2K ($42.2K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Mobeck Kenneth S. | Chief Financial Officer | A | 120,000 | $0.00 | $0.00 |
| May 12, 2026 | Mobeck Kenneth S. | Chief Financial Officer | A | 144,141 | $0.00 | $0.00 |
| May 12, 2026 | Shah Sanket | Gen Counsel & Corp Secretary | A | 67,500 | $0.00 | $0.00 |
| May 12, 2026 | Shah Sanket | Gen Counsel & Corp Secretary | A | 75,000 | $0.00 | $0.00 |
| May 12, 2026 | WILLSEY LANCE | Director | A | 114,285 | $0.00 | $0.00 |
| May 12, 2026 | Rhodes Ryan | Chief Executive Officer | A | 304,500 | $0.00 | $0.00 |
| May 12, 2026 | Rhodes Ryan | Chief Executive Officer | A | 390,000 | $0.00 | $0.00 |
| May 12, 2026 | Annen Steven | SVP, Marketing & Product Mgmt. | A | 90,000 | $0.00 | $0.00 |
| May 12, 2026 | Annen Steven | SVP, Marketing & Product Mgmt. | A | 100,000 | $0.00 | $0.00 |
| May 11, 2026 | LEVINE JOSHUA | Director | BUY | 10,000 | $4.22 | $42.2K |
8 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 1 mixed, 6 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
4/10
EDAP TMS SA announced it will operate under the new corporate name 'FocalTherics' and change its Nas
May 29, 2026
BEARISH
DEFA14A
6/10
EDAP TMS SA filed its management report for the 2025 fiscal year ahead of the June 26, 2026 annual g
May 14, 2026
NEUTRAL
DEFA14A
3/10
EDAP TMS SA filed a DEFA14A providing notice of its 2026 Ordinary and Extraordinary General Meeting
May 14, 2026
MIXED
8-K
6/10
EDAP reported Q1 2026 total revenue of $17.8M (up 25% YoY from $14.3M), driven by record HIFU revenu
May 7, 2026
NEUTRAL
PRESS-RELEASE
3/10
EDAP announced it will release Q1 2026 financial results on May 7, 2026, followed by a conference ca
Apr 16, 2026
NEUTRAL
EFFECT
4/10
EDAP TMS SA's shelf registration (S-3) has become effective, allowing the company to issue up to $12
Apr 1, 2026
NEUTRAL
S-3/A
4/10
EDAP TMS S.A. filed an S-3/A amendment to register up to $125 million in securities, including ordin
Mar 27, 2026
NEUTRAL
S-3
5/10
EDAP TMS S.A. filed an S-3 shelf registration to raise up to $125 million through future offerings o
Mar 25, 2026
NEUTRAL
3/10
EDAP TMS announced a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinic
May 14, 2026
MIXED
6/10
EDAP reported record full-year 2025 HIFU revenue with 39% YoY growth, driven by strong Focal One sys
Mar 25, 2026
NEUTRAL
3/10
EDAP TMS SA announced it will release its fourth quarter and full year 2025 financial results on Mar
Mar 4, 2026
Current analyst consensus: Buy (67% buy). Based on 9 analysts: 2 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.83 mean target
+35.0% upside
Strong Buy (3.00)
$3.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $4.32 |
| Target Low | $3.00 |
| Target Mean | $5.83 |
| Target Median | $4.50 |
| Target High | $10.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.24 | $-0.17 | -17.7% | +6.8% | — | $0.0B | 3.7% | 2 |
| Next Q 2026-09-30 |
$-0.23 | $-0.23 | $-0.22 | -50.0% | -2.3% | — | $0.0B | 3.0% | 2 |
| Current FY 2026-12-31 |
$-0.82 | $-0.86 | $-0.78 | -2.6% | +1.2% | — | $0.1B | 3.7% | 2 |
| Next FY 2027-12-31 |
$-0.59 | $-0.64 | $-0.54 | 28.1% | +0.2% | 0↑ 1↓ | $0.1B | 6.5% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.205 | |
| 7d ago | $-0.190 | -0.015 |
| 30d ago | $-0.220 | +0.015 |
| 60d ago | $-0.170 | -0.035 |
| 90d ago | $-0.170 | -0.035 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Apr 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Mar 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Feb 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jan 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 29, 2026
other
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
<p>, May 29, 2026 (GLOBE NEWSWIRE) -- <b>EDAP Announces Corporate Name Change to FocalTherics</b><sup><b>™</b></sup><b> to Reflect Exclusive Focus o
May 21, 2026
other
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
<p align="center">, May 21, 2026 (GLOBE NEWSWIRE) -- <strong>EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference</strong></p>
May 14, 2026
contract
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
<p>, May 14, 2026 (GLOBE NEWSWIRE) -- <b>AUSTIN, Texas – May 14, 2026</b> – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a
May 13, 2026
other
EDAP | Focal One to Host Investor Day on June 1, 2026
<p align="center">, May 13, 2026 (GLOBE NEWSWIRE) -- <b>EDAP | Focal One to Host Investor Day on June 1, 2026</b></p>
May 7, 2026
earnings
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
<p>, May 07, 2026 (GLOBE NEWSWIRE) -- <img height="45.46px" name="GNW_RichHtml_IMG" src="https://ml-eu.globenewswire.com/Resource/Download/396d05d0-
May 7, 2026
earnings_calendar
EDAP Q1 2026 Earnings Scheduled — 2026-05-07
Apr 30, 2026
other
EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer
<p>, April 30, 2026 (GLOBE NEWSWIRE) -- <img height="45.46px" name="GNW_RichHtml_IMG" src="https://ml-eu.globenewswire.com/Resource/Download/ed6b233
Apr 16, 2026
earnings
EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026
<p align="center">, April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026</p>
Mar 25, 2026
earnings
EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue
<p align="center">EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue </p>
Mar 25, 2026
earnings_calendar
EDAP Q4 2025 Earnings After Market Close — 2026-03-25
Mar 10, 2026
other
EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference
<p align="left">EDAP to Present at Oppenheimer 36<sup>th</sup> Annual Healthcare MedTech & Services Conference</p>
Mar 4, 2026
earnings
EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026
<p align="left">EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026</p>